These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 36057393)
1. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain). Chico-Sánchez P; Gras-Valentí P; Algado-Sellés N; Jiménez-Sepúlveda N; Vanaclocha H; Peiró S; Burgos JS; Berenguer A; Navarro D; Sánchez-Payá J; Prev Med; 2022 Oct; 163():107237. PubMed ID: 36057393 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain. Jiménez-Sepúlveda N; Gras-Valentí P; Chico-Sánchez P; Castro-García JM; Ronda-Pérez E; Vanaclocha H; Peiró S; Burgos JS; Ana Berenguer ; Navarro D; Sánchez-Payá J; Vaccine; 2024 Jul; 42(19):4011-4021. PubMed ID: 38760269 [TBL] [Abstract][Full Text] [Related]
3. The Waning of BNT162b2 Vaccine Effectiveness for SARS-CoV-2 Infection Prevention over Time: A Test-Negative Study in Health Care Professionals of a Health Department from January 2021 to December 2021. Jiménez-Sepúlveda N; Chico-Sánchez P; Castro-García JM; Escribano-Cañadas I; Merino-Lucas E; Ronda-Pérez E; Sánchez-Payá J; Gras-Valentí P; On Behalf Of The Covid-Preventive Medicine Group Int J Environ Res Public Health; 2022 Oct; 19(21):. PubMed ID: 36360764 [TBL] [Abstract][Full Text] [Related]
4. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236 [TBL] [Abstract][Full Text] [Related]
5. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of the first dose of BNT162b2 vaccine to preventing covid-19 in healthcare personnel.]. Gras-Valentí P; Chico-Sánchez P; Algado-Sellés N; Jiménez-Sepúlveda NJ; Gómez-Sotero IL; Fuster-Pérez M; Cartagena-Llopis L; Sánchez-Valero M; Cerezo-Milán P; Martínez-Tornero I; Tremiño-Sánchez L; Nadal-Morante V; Monerris-Palmer M; Esclapez-Martínez A; MorenodeArcos-Fuentes E; Escalada-Martín I; Escribano-Cañadas I; Merino-Lucas E; Rodríguez-Díaz JC; Sánchez-Payá J Rev Esp Salud Publica; 2021 Apr; 95():. PubMed ID: 33913444 [TBL] [Abstract][Full Text] [Related]
7. Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021. Winkelman TNA; Rai NK; Bodurtha PJ; Chamberlain AM; DeSilva M; Jeruzal J; Johnson SG; Kharbanda A; Klyn N; Mink PJ; Muscoplat M; Waring S; Yu Y; Drawz PE JAMA Netw Open; 2022 Mar; 5(3):e225018. PubMed ID: 35357452 [TBL] [Abstract][Full Text] [Related]
8. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population. Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940 [TBL] [Abstract][Full Text] [Related]
9. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization. Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305 [TBL] [Abstract][Full Text] [Related]
10. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. Liu B; Gidding H; Stepien S; Cretikos M; Macartney K Vaccine; 2022 Oct; 40(43):6288-6294. PubMed ID: 36180375 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC; BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165 [TBL] [Abstract][Full Text] [Related]
12. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease. Beckley M; Olson AK; Portman MA JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521 [TBL] [Abstract][Full Text] [Related]
14. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021. Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. Lin DY; Gu Y; Wheeler B; Young H; Holloway S; Sunny SK; Moore Z; Zeng D N Engl J Med; 2022 Mar; 386(10):933-941. PubMed ID: 35020982 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. Thompson MG; Stenehjem E; Grannis S; Ball SW; Naleway AL; Ong TC; DeSilva MB; Natarajan K; Bozio CH; Lewis N; Dascomb K; Dixon BE; Birch RJ; Irving SA; Rao S; Kharbanda E; Han J; Reynolds S; Goddard K; Grisel N; Fadel WF; Levy ME; Ferdinands J; Fireman B; Arndorfer J; Valvi NR; Rowley EA; Patel P; Zerbo O; Griggs EP; Porter RM; Demarco M; Blanton L; Steffens A; Zhuang Y; Olson N; Barron M; Shifflett P; Schrag SJ; Verani JR; Fry A; Gaglani M; Azziz-Baumgartner E; Klein NP N Engl J Med; 2021 Oct; 385(15):1355-1371. PubMed ID: 34496194 [TBL] [Abstract][Full Text] [Related]
17. Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI). Katz MA; Harlev EB; Chazan B; Chowers M; Greenberg D; Peretz A; Tshori S; Levy J; Yacobi M; Hirsch A; Amichay D; Weinberger R; Dor AB; Taraday EK; Reznik D; Chayat CB; Sagas D; Zvi HB; Berdinstein R; Rashid G; Avni YS; Mandelboim M; Zuckerman N; Rainy N; Akriv A; Dagan N; Kepten E; Barda N; Balicer RD Vaccine; 2022 Jan; 40(3):512-520. PubMed ID: 34903372 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022. Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M; Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Martínez-Baz I; Miqueleiz A; Casado I; Navascués A; Trobajo-Sanmartín C; Burgui C; Guevara M; Ezpeleta C; Castilla J; Euro Surveill; 2021 May; 26(21):. PubMed ID: 34047271 [TBL] [Abstract][Full Text] [Related]
20. The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis. Kow CSC; Ramachandram DS; Hasan SS Inflammopharmacology; 2022 Feb; 30(1):149-157. PubMed ID: 35099680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]